Glenmark Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 46.00 Cr
as on 28-06-2024
- Paid Up Capital ₹ 24.51 Cr
as on 28-06-2024
- Company Age 13 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 2.44%
(FY 2023)
- Profit 11.52%
(FY 2023)
- Ebitda 4.26%
(FY 2023)
- Net Worth 4.08%
(FY 2023)
- Total Assets 9.35%
(FY 2023)
About Glenmark Life Sciences
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 543322 and on the National Stock Exchange(NSE) under GLS.
The Corporate was formerly known as Glenmark Life Sciences Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 46.00 Cr and a paid-up capital of Rs 24.51 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Glenmark Life Sciences Limited India are Tushar Mistry as Cfo, Yasir Rawjee as Ceo, and Rudalf Corriea as Company Secretary. Kaushikbhai Patel, Hiren Patel, Vijaykumar Shah, and Four other members serve as directors at the Company.
Industry
Company Details
- Location
Solapur, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Glenmark Life Sciences?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yasir Rawjee  | Managing Director | 13-Aug-2019 | Current |
| Tushar Mistry | CFO | 01-Jun-2022 | Current |
| Rudalf Corriea | Company Secretary | 23-Feb-2021 | Current |
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Manju Agarwal | Director | 30-Oct-2020 | Current |
| Kaushikbhai Patel | Additional Director | 14-Mar-2024 | Current |
| Hiren Patel | Additional Director | 21-Mar-2024 | Current |
| Vijaykumar Shah | Additional Director | 14-Mar-2024 | Current |
| Taruvai Easwar | Director | 08-Jan-2021 | Current |
| Vinod Naik | Whole-Time Director | 21-Oct-2022 | Current |
Financial Performance and Corporate Structure Insights of Glenmark Life Sciences.
Glenmark Life Sciences Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.44% increase. The company also saw a substantial improvement in profitability, with a 11.52% increase in profit. The company's net worth moved up by a moderate rise of 4.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glenmark Life Sciences?
In 2022, Glenmark Life Sciences had a promoter holding of 82.85% and a public holding of 17.15%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nuvoco Vistas Corporation LimitedActive 25 years 10 monthsKaushikbhai Patel and Hiren Patel are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Glenmark Life Sciences?
Glenmark Life Sciences has a workforce of 1899 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glenmark Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glenmark Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
